TrialBlood2008
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
Graham M Mead et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
84 papers cite itlatest 60 shown
this paperpooled ittrialcites it